Abstract
Purpose: Measurable tumors that involve vaginal tissue, including primary vaginal cancer and recurrent endometrial cancer (after prior hysterectomy), are often treated using a combination of external beam radiotherapy (EBRT) and fractionated high-dose-rate (HDR) brachytherapy (BT). BT boost may be achieved with a variety of applicator types, mainly intracavitary (IC) single channel (SCVC) or multichannel vaginal cylinder (MCVC), or an interstitial (IS) implant. In comparison to SCVC, MCVC features an arrangement of peripheral catheters that allow preferential treatment of localized surface targets to higher doses, without the need for an invasive IS component.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
